CANOPY_1170x120_9-21-20

Remdesivir

Dr. Reddy’s enters into a licensing agreement with Gilead Sciences for Remdesivir

Dr. Reddy’s enters into a licensing agreement with Gilead Sciences for Remdesivir

PRINCETON, N.J.— Dr. Reddy’s announced that it has entered into a non-exclusive Licensing Agreement with Gilead Sciences that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for COVID-19, in 127 countries including India. Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this

Senators Markey and Warren, Rep. Pressley call for transparency in remdesivir

Senators Markey and Warren, Rep. Pressley call for transparency in remdesivir

WASHINGTON – Senators Edward J. Markey (D, Mass.) and Elizabeth Warren (D, Mass.) and Congresswoman Ayanna Pressley (MA-07) sent a letter on Friday calling on Vice President Mike Pence and the Secretary of Health and Human Services to immediately explain how the federal government is distributing remdesivir, a drug recently approved to treat COVID-19. Reports

FDA Issues emergency use authorization for remdesivir for treatment of COVD-19

FDA Issues emergency use authorization for remdesivir for treatment of COVD-19

WASHINGTON — On Friday, the U.S. Food and Drug Administration issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. While there is limited information known about the safety and effectiveness of using remdesivir to treat people in the

NIH clinical trial shows remdesivir speeds up recovery from advanced COVID-19

NIH clinical trial shows remdesivir speeds up recovery from advanced COVID-19

BETHESDA, Md.— Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21. The trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by the National Institute

Gilead haults access to experimental COVID-19 drug Remdesivir due to massive demand

Gilead haults access to experimental COVID-19 drug Remdesivir due to massive demand

FOSTER CITY, Calif. — Gilead Sciences has temporarily stopped granting patients access to Remdesivir, its experimental drug against the novel coronavirus, citing “overwhelming demand,” the company stated this week. Gilead Sciences said in a statement that it is focused on processing previously approved requests, and that it is developing a new system that it says